Veradermics is trading 4.3% down at $114.41 as broader risk-off sentiment and escalating geopolitical tensions weigh on the biotech sector.
- The XBI biotech ETF has declined approximately 2.7% while major indices like the Nasdaq trade lower as investors react to U.S.–Iran tensions and unwind risk exposure.
- With no company-specific catalysts reported today, the move appears driven by macro pressure and sector-wide profit-taking following the stock's strong post-IPO run.